Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy - Final evaluation document

In DRAFT guidance, NICE recommends nivolumab as an option for treating locally advanced or metastatic squamous NSCLC in adults after chemotherapy, only if it is stopped at 2 years of uninterrupted treatment, or earlier if their disease progresses.

SPS commentary:

It is additionally only recommended if they have not had a PD-1 or PD-L1 inhibitor before, and if the company provides nivolumab according to the commercial arrangement.


National Institute for Health and Care Excellence